Hikma said FY 2025 revenue rose to USD 3.3 billion (+7.0%), while operating profit fell to USD 542 million (-11.0%) after a USD 72 million legal settlement linked to sodium oxybate. Profit attributable to shareholders increased to USD 402 million (+12.0%) and basic EPS rose to 182 cents (+12.0%). Cashflow from operating activities was USD 436 million (-23.0%). The company lifted total dividend to 84 cents (+5.0%) and announced a share buyback of up to USD 250 million to be executed during 2026. By segment in FY 2025, Injectables revenue was USD 1.4 billion (+9.0%), Branded revenue USD 849 million (+10.0%) and Hikma Rx revenue USD 1.0 billion (+1.0%). Hikma highlighted 84 product launches during 2025, including Tyzavan in the US, the launch of its first US biosimilar (ustekinumab), and continued roll-out of palbociclib and dapagliflozin tablets in MENA; it also signed 14 MENA deals and expanded its Celltrion partnership for six additional biosimilars. Corporate updates included leadership changes effective immediately, with Victoria Hull appointed Chair, and a CFO search underway with Areb Kurdi named acting CFO. For 2026, Hikma guided for group revenue growth of 2.0% to 4.0% and core operating profit of USD 720 million to USD 770 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hikma Pharmaceuticals plc published the original content used to generate this news brief on February 26, 2026, and is solely responsible for the information contained therein.